N/A
Completed N=173
Sleep Apnea Study in Adults Using DreamPort-Eclipse and a Traditional Nasal Mask
Source: ClinicalTrials.gov NCT05818540 ↗Enrolled (actual)
173
Serious AEs
0.0%
Results posted
Nov 2025
Primary outcomePrimary: Apnea-Hypopnea Index (AHI) — 2.7; 2.5 events/h
Summary
The Randomized Controlled Trial of Bleep DreamPort-Eclipse Study is a two-arm, randomized, prospective, non-blinded study to assess the effectiveness of the novel CPAP human interface design to improve leak, AHI, and pressure compared to a traditional nasal mask.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Apnea-Hypopnea Index (AHI) |
2.7; 2.5 | — |
| PRIMARY Leak |
3.66; 3.01 | — |
| PRIMARY CPAP Device Pressure (P95) |
8.93; 8.62 | — |
| SECONDARY Participant Satisfaction With the Mask Choice |
4.3; 4.1 | — |
| SECONDARY Percentage of Participants Who Could Tolerate the Mask Well (Mask Tolerability) |
41; 55 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female ≥18 years old who are impacted by obstructive sleep apnea and currently are familiar with a CPAP device
Exclusion Criteria
- Any medical or behavioral conditions that would compromise subject safety
- Under the age of 18 years old
Data sourced from ClinicalTrials.gov (NCT05818540). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.